Gene Location [1]
Variant Type

TFE3 Fusion is present in 0.10% of AACR GENIE cases, with translocation-associated renal cell carcinoma, alveolar soft part sarcoma, renal cell carcinoma, epithelioid hemangioendothelioma, and pecoma having the greatest prevalence [4].

Top Disease Cases with TFE3 Fusion

Significance of TFE3 Fusion in Diseases

Renal Cell Carcinoma +

Translocation-Associated Renal Cell Carcinoma +

Non-Clear Cell Renal Cell Carcinoma +

Malignant Solid Tumor +

Chromophobe Renal Cell Carcinoma +

Papillary Renal Cell Carcinoma +

Unclassified Renal Cell Carcinoma +

Soft Tissue Sarcoma +

Non-Hodgkin Lymphoma +

Sarcomatoid Renal Cell Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.